CONGENITAL ADRENAL HYPERPLASIA DUE TO 21-HYDROXYLASE DEFICIENCY
Clinical trials for CONGENITAL ADRENAL HYPERPLASIA DUE TO 21-HYDROXYLASE DEFICIENCY explained in plain language.
Never miss a new study
Get alerted when new CONGENITAL ADRENAL HYPERPLASIA DUE TO 21-HYDROXYLASE DEFICIENCY trials appear
Sign up with your email to follow new studies for CONGENITAL ADRENAL HYPERPLASIA DUE TO 21-HYDROXYLASE DEFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New infusion drug hopes to tame rare hormone disorder
Disease control Recruiting nowThis early-stage trial is testing a new drug called Lu AG13909 in 42 adults with congenital adrenal hyperplasia (CAH), a rare genetic condition that disrupts hormone production. The study aims to check the drug's safety, how it moves through the body, and its effects on hormone l…
Matched conditions: CONGENITAL ADRENAL HYPERPLASIA DUE TO 21-HYDROXYLASE DEFICIENCY
Phase: PHASE1, PHASE2 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New Once-Daily pill could simplify CAH treatment
Disease control Recruiting nowThis study tests whether a once-daily dual-release hydrocortisone pill (Plenadren) works better than standard multiple-dose glucocorticoids for adults with congenital adrenal hyperplasia. The trial will enroll 150 adults and measure changes in cholesterol, blood sugar, weight, bl…
Matched conditions: CONGENITAL ADRENAL HYPERPLASIA DUE TO 21-HYDROXYLASE DEFICIENCY
Phase: PHASE4 • Sponsor: Federico II University • Aim: Disease control
Last updated Jun 26, 2026 17:55 UTC